A Retrospective Non-interventional Study to Evaluate the Use of Seroquel Extended Release (XR) and Immediate Release (IR) in the Clinical Practice of Inpatients With Schizophrenia

NCT ID: NCT01214135

Last Updated: 2011-01-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this non-interventional study is to investigate how Seroquel XR and Seroquel IR are used in the clinical practice of inpatients with schizophrenia. This will be done by a retrospective review of medical records to evaluate patients treated with Seroquel XR or Seroquel IR as primary antipsychotic treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients with a diagnosis of schizophrenia who have been hospitalized and received at least one dose of Seroquel XR or Seroquel IR during the study period (1st of July 2009 - 30th of September 2010).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of schizophrenia.
* At least one dose of Seroquel XR or Seroquel IR during the study period (1st of July 2009 - 30th of September 2010).
* Hospitalization due to psychotic symptoms at any time during the study period (1st of July 2009 - 30th of September 2010) and with admission and discharge dates available.

Exclusion Criteria

* Participation in a clinical trial during the study period.
* Treatment in forensic care according to LRV ("Lagen om Rättspsykiatrisk Vård").
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr Eva Dencker Vansvik, MD

Role: STUDY_DIRECTOR

AstraZeneca

Dr Lars Eriksson, MD

Role: PRINCIPAL_INVESTIGATOR

Rättspsykiatriska Vårdkedjan, Hisings-Backa, Sweden

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Falköping, , Sweden

Site Status

Research Site

Gothenburg, , Sweden

Site Status

Research Site

Helsingborg, , Sweden

Site Status

Research Site

Karlskrona, , Sweden

Site Status

Research Site

Karlstad, , Sweden

Site Status

Research Site

Lund, , Sweden

Site Status

Research Site

Malmo, , Sweden

Site Status

Research Site

Mölndal, , Sweden

Site Status

Research Site

Öjebyn, , Sweden

Site Status

Research Site

Stockholm, , Sweden

Site Status

Research Site

Trollhättan, , Sweden

Site Status

Research Site

Umeå, , Sweden

Site Status

Research Site

Uppsala, , Sweden

Site Status

Research Site

Vaxjo, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

References

Explore related publications, articles, or registry entries linked to this study.

Eriksson L, Hallerback T, Jorgensen L, Carlborg A. Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study. Ther Adv Psychopharmacol. 2012 Dec;2(6):217-26. doi: 10.1177/2045125312453935.

Reference Type DERIVED
PMID: 23983980 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-NSE-SER-2010/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Seroquel XR in Adults With Schizophrenia
NCT00852631 TERMINATED PHASE3
Quetiapine XR in Schizophrenic Patients
NCT01071135 TERMINATED PHASE3